Shaanxi Panlong Pharmaceutical (002864)
Search documents
盘龙药业: 董事会审计委员会实施细则
Zheng Quan Zhi Xing· 2025-08-27 14:16
陕西盘龙药业集团股份有限公司董事会审计委员会实施细则 陕西盘龙药业集团股份有限公司 (2025 年 8 月) 第一章 总则 第一条 为强化董事会决策功能,做到事前审计、专业审计,确保董事会对 经理层的有效监督,完善公司治理结构,根据《中华人民共和国公司法》、《深 圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》《陕西盘 龙药业集团股份有限公司章程》(以下简称"公司章程")等规定,公司特设置 董事会审计委员会,并制定本实施细则。 第二条 董事会审计委员会是董事会设置的专门工作机构;行使《公司法》 规定的监事会的职权,负责公司内、外部审计的沟通、监督和核查工作。 第三条 公司须为审计委员会提供必要的工作条件,配备专门人员或者机构 承担审计委员会的工作联络、会议组织、材料准备和档案管理等日常工作。审计 委员会履行职责时,上市公司管理层及相关部门须给予配合。审计委员会发现公 司经营情况异常,可以进行调查;必要时,可以聘请中介机构协助其工作,费用 由公司承担。 第二章 人员组成 第四条 审计委员会由三名董事组成,应当为不在公司担任高级管理人员的 董事;独立董事过半数。公司董事会成员中的职工代表可以成为 ...
盘龙药业: 董事和高级管理人员离职管理制度
Zheng Quan Zhi Xing· 2025-08-27 14:16
陕西盘龙药业集团股份有限公司董事、高级管理人员离职管理制度 陕西盘龙药业集团股份有限公司 董事、高级管理人员离职管理制度 (2025 年 8 月) 第一章 总则 第一条 为规范陕西盘龙药业集团股份有限公司(以下简称"公司")董事、 高级管理人员离职相关事宜,确保公司治理结构的稳定性和连续性,维护公司及 股东的合法权益,公司根据《中华人民共和国公司法》(以下简称"《公司法》") 等法律法规、规范性文件及《陕西盘龙药业集团股份有限公司章程》(以下简称 "《公司章程》")的有关规定,结合公司实际情况,制定本制度。 第二条 本制度适用于公司董事(含独立董事)、高级管理人员因任期届满、 辞职、被解除职务或其他原因离职的情形。 第五条 董事提出辞任的,公司应当在 60 日内完成补选,确保董事会及其专 门委员会构成符合法律、行政法规和《公司章程》的规定。 第六条 公司董事、高级管理人员在任职期间出现下列情形的,公司应当依 法解除其职务: 第二章 离职情形与程序 第三条 公司董事和高级管理人员可以在任期届满以前辞任,董事和高级管 理人员辞任应当向公司提交书面辞职报告,辞职报告中应说明辞任时间、辞任原 因、辞去的职务、辞任后是 ...
盘龙药业: 董事会可持续战略发展委员会实施细则
Zheng Quan Zhi Xing· 2025-08-27 14:16
《上市公司治理准则》、 《陕西盘龙药业集团股份有限公司公司章程》(以下简称"公司章程")等规定, 公司董事会下设董事会可持续战略发展委员会,并制定本实施细则。 陕西盘龙药业集团股份有限公司董事会可持续战略发展委员会实施细则 陕西盘龙药业集团股份有限公司 (2025 年 8 月) 第一章 总则 第一条 为适应公司战略发展需要,增强公司核心竞争力,确定公司发展规 划,健全投资决策程序,加强决策科学性,提高重大投资决策的效益和决策的质 量,完善公司治理结构,根据《中华人民共和国公司法》、 第二条 董事会可持续战略发展委员会是董事会按照股东会决议设置的专 门工作机构,主要负责对公司长期发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第三条 可持续战略发展委员会由三名董事组成,其中应至少包括一名独立 董事。 第四条 可持续战略发展委员会委员由董事长、二分之一以上独立董事或者 全体董事的三分之一提名,并由董事会选举产生。 第五条 可持续战略发展委员会设主任委员一名,负责主持可持续战略发展 委员会工作,由委员选举产生,并报董事会备案。 第六条 可持续战略发展委员会任期与董事会任期一致,委员任期届满,连 选可以 ...
盘龙药业: 董事和高级管理人员所持公司股份及其变动管理规则
Zheng Quan Zhi Xing· 2025-08-27 14:16
General Principles - The rules are established to strengthen the management of shares held by directors and senior management of Shaanxi Panlong Pharmaceutical Group Co., Ltd. and to maintain market order [1] - The rules are based on relevant laws and regulations including the Company Law and Securities Law of the People's Republic of China [1] Share Management - Directors and senior management are prohibited from transferring shares under certain conditions, such as within one year of the company's stock listing or during investigations related to securities violations [3] - The maximum amount of shares that can be transferred by directors and senior management in a year is limited to 25% of their total holdings, with exceptions for certain circumstances [4] - Newly acquired shares can only be transferred at a rate of 25% in the year they are acquired, and any increase in shares due to company actions will proportionally increase the transferable amount [4] Disclosure Requirements - Directors and senior management must report their share transactions to the company and disclose relevant information to the stock exchange within two trading days of any change [12] - A detailed plan must be disclosed prior to any share reduction, including the number of shares, time frame, and reasons for the reduction [5][7] - Any shareholding changes due to court-ordered transactions must be disclosed within two trading days of receiving the execution notice [6] Additional Regulations - Directors and senior management must ensure that their immediate family members and related parties do not engage in insider trading [24] - The rules apply to various scenarios including share increases due to capital increases or stock options [18] - The company is responsible for ensuring the accuracy and timeliness of the reported data [25]
盘龙药业: 总裁工作细则
Zheng Quan Zhi Xing· 2025-08-27 14:16
陕西盘龙药业集团股份有限公司总裁工作细则 指引第 1 号—主板上市公司规范运作》、《陕西盘龙药业集团股份有限公司章程》 (以下简称"公司章程")的有关规定,制定本细则。 第二条 公司依法设置总裁。 第三条 总裁由董事会聘任或者解聘,对董事会负责,根据公司章程的规定 或者董事会的授权行使职权。总裁列席董事会会议。 第四条 总裁主持公司日常生产经营和管理工作,组织实施董事会决议。 第二章 总裁的任职资格与任免程序 陕西盘龙药业集团股份有限公司 (2025 年 8 月) 第一章 总则 第一条 按照建立现代企业制度的要求,进一步完善陕西盘龙药业集团股份 有限公司(以下简称"公司"或"本公司")治理结构,根据《中华人民共和国 公司法》、 《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律监管 第五条 总裁应当具备下列条件: (一)具有较丰富的经济理论知识、管理知识及实践经验,具有较强的经营 管理能力; (二)具有调动员工积极性、建立合理的组织机构、协调各种内外关系和统 揽全局的能力; (三)具有一定年限的企业管理或经济工作经历,精通本行业、熟悉多种行 业的生产经营业务和掌握国家有关政策、法律、法规; (四) ...
盘龙药业: 内部审计管理制度
Zheng Quan Zhi Xing· 2025-08-27 14:16
Core Viewpoint - The internal audit management system of Shaanxi Panlong Pharmaceutical Group Co., Ltd. aims to enhance internal audit work, reduce decision-making risks, improve economic efficiency, and ensure healthy business operations in accordance with relevant laws and regulations [1][2]. Group 1: General Principles - The internal audit management system is established based on the Audit Law of the People's Republic of China and other regulatory guidelines to strengthen internal audit work [1]. - The audited entities include various departments, subsidiaries, and responsible personnel within the company [1]. Group 2: Organizational Structure and Responsibilities - The company has established an audit department as the internal audit body, responsible for supervising business activities, risk management, internal controls, and financial information [2]. - The audit department is independent and should not be under the leadership of the finance department [2]. - The audit department reports to the board of directors and is supervised by the audit committee [2]. Group 3: Scope and Authority - The audit department conducts audits on financial plans, cost plans, financial activities, major economic contracts, internal control systems, and compliance with financial regulations [4][5]. - The audit department has the authority to request necessary documents, attend relevant meetings, and propose temporary measures against violations of financial regulations [5]. Group 4: Audit Types and Methods - The main types of audits include financial audits and special audits focusing on the legality and effectiveness of economic activities [9]. - Audit methods include document review, observation, inquiry, and analytical review to gather sufficient and relevant evidence [6]. Group 5: Reporting and Evaluation - The audit department must report at least quarterly to the board or audit committee on the execution of the audit plan and any issues found [6]. - The audit committee oversees the audit department and ensures that internal control evaluations are conducted regularly [7][8]. Group 6: Confidentiality and Personnel - The audit department must maintain confidentiality and not disclose internal audit information to unauthorized parties [12]. - Audit personnel are required to possess necessary professional knowledge and adhere to ethical standards in their work [20][24].
盘龙药业: 中小投资者单独计票机制实施细则
Zheng Quan Zhi Xing· 2025-08-27 14:16
陕西盘龙药业集团股份有限公司中小投资者单独计票机制实施细则 陕西盘龙药业集团股份有限公司 (2025 年 8 月) 第一章 总则 第一条 为进一步落实国家有关加强资本市场中小投资者合法权益保护工作 意见,充分保障中小投资者依法行使权利,完善公司股东会表决相关重大事项 时对中小投资者的投票情况进行单独计票的流程及披露机制,根据有关法律、 法规和规范性文件,结合陕西盘龙药业集团股份有限公司(以下简称"公司") 实际情况,制定本细则。 (一)利润分配方案、资本公积金转增股本方案、弥补亏损方案; (二)修改公司章程中涉及中小投资者利益的条款; (三)发行公司证券; (四)重大资产重组; (五)公司合并、分立、解散、清算; (六)重大关联交易; (七)股权激励计划; (八)重大对外投资、对外担保、对外提供财务资助; (九)选举和更换非由职工代表担任的董事,决定有关董事、高级管理人 员的报酬事项; 第二条 本细则所称中小投资者是指股东会股权登记日除公司董事、高级管 理人员以及单独或者合计持有公司5%以上(含本数)股份的股东以外的其他股 东。 第二章 单独计票的适用范围 第三条 股东会审议影响中小投资者利益的重大事项时,对 ...
盘龙药业: 信息披露管理制度
Zheng Quan Zhi Xing· 2025-08-27 14:16
Core Viewpoint - The document outlines the information disclosure management system of Shaanxi Panlong Pharmaceutical Group Co., Ltd, emphasizing the importance of timely, accurate, and complete information disclosure to protect the rights of investors and comply with relevant laws and regulations. Group 1: General Principles - The company aims to ensure that all disclosed information is true, accurate, complete, timely, and fair, without any false records or misleading statements [3][4][5] - Information disclosure obligations apply to the company, its directors, senior management, and other relevant parties, ensuring that significant events affecting stock prices are disclosed promptly [2][6] Group 2: Disclosure Procedures - The company must disclose periodic reports, including annual and interim reports, which should be audited by qualified accounting firms [10][21] - The disclosure of significant events must occur immediately when they are known, especially if they could impact stock prices [18][22] Group 3: Responsibilities and Oversight - The board of directors is responsible for establishing and implementing the information disclosure management system, ensuring compliance and timely disclosures [15][19] - The audit committee and independent directors are tasked with supervising the implementation of the disclosure system and addressing any deficiencies [8][29] Group 4: Specific Disclosure Requirements - The company must disclose information regarding major shareholders, changes in control, and any significant legal proceedings that could affect its financial status [20][34] - Any changes in the company's financial performance or significant operational events must be reported to maintain transparency with investors [14][16]
盘龙药业: 信息披露暂缓、豁免管理制度
Zheng Quan Zhi Xing· 2025-08-27 14:16
General Principles - The company establishes a management system for the deferral and exemption of information disclosure to regulate the behavior of the company and other information disclosure obligors, enhance information disclosure supervision, and protect investors' legitimate rights and interests [1][2] - The company and other information disclosure obligors must disclose information truthfully, accurately, completely, timely, and fairly, and must not abuse deferral or exemption to evade disclosure obligations or mislead investors [1][2] Scope and Management of Deferral and Exemption - The company can exempt disclosure if there is sufficient evidence that the information involves state secrets or other matters that may violate state confidentiality regulations [2][3] - The company has an obligation to protect state secrets and must not leak them through any form of information disclosure or interaction with investors [2][3] - Information involving commercial secrets can be deferred or exempted if it meets certain conditions, such as being core technology information that could lead to unfair competition if disclosed [2][3] Internal Review Procedures - The company’s board secretary is responsible for organizing and coordinating the deferral and exemption of information disclosure, with the board office handling daily operations [5] - If a deferral or exemption application is not approved by the board secretary or the chairman, the company must disclose the information in accordance with securities regulatory requirements [5] Reporting and Documentation - The company must register details of the deferral or exemption, including the type of documents involved and the internal review procedures [4][5] - After the annual, semi-annual, or quarterly reports are announced, the company must submit relevant registration materials regarding deferrals or exemptions to the local securities regulatory bureau and stock exchange within ten days [4][5]
盘龙药业: 累积投票制度实施细则
Zheng Quan Zhi Xing· 2025-08-27 14:16
陕西盘龙药业集团股份有限公司累积投票制度实施细则 陕西盘龙药业集团股份有限公司 (2025 年 月) 第一章 总则 第一条 为进一步完善公司法人治理结构,规范公司董事的选举,保证股东 充分行使权利,维护中小投资者利益,根据《中华人民共和国公司法》、 《上市公 司治理准则》、 《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律 股东会主持人应在会上向出席会议股东明确说明以上注意事项,计票人员应 认真核对选票,以保证投票的公正、有效。 监管指引第 1 号—主板上市公司规范运作》及公司章程的有关规定,特制订本实 施细则。 第二条 本细则所指累积投票制,是指公司股东会选举董事时,出席股东会 的股东所拥有的投票权等于其所持有的股份总数乘以应选董事人数之积,出席会 议股东可以将其拥有的投票权全部投向一位董事候选人,也可以将其拥有的投票 权分散投向多位董事候选人,获选董事按应选董事人数依次以得票较高者确定。 股东会就选举董事进行表决时,实行累积投票制。 本细则所称的董事包括独立董事和非独立董事,不包括职工代表董事,由职 工代表担任的董事由公司职工民主选举产生或更换,不适用本实施细则的相关规 定。 第三条 为确保 ...